Correction to: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group (Nature Communications, (2024), 15, 1, (1985), 10.1038/s41467-024-45974-w)

Correction to: Nature Communicationshttps://doi.org/10.1038/s41467-024-45974-w, published online 05 March 2024 The original version of the article file contained some inaccuracies in the Discussion section. The following corrections have now been made in the revised PDF and HTML versions of the article file. The second part of the original statement “In a small population of 44 patients, they obtained a median PFS of 22.4 months, which is encouraging; however, the number of previous treatment lines was not reported²⁷” was inaccurate since one of the inclusion criteria of the cited trial (ref. ²⁷) was “Participant has received 2 previous courses of platinum-containing therapy”. The original sentence has now been rephrased as “In a small population of 44 patients, they obtained a median PFS of 22.4 months, which is encouraging²⁷.” In addition, in the original sentence “Studies evaluating different triplet combinations are underway^37,38”, ref. ³⁸ was incorrectly cited since related to the publication of the study protocol for the trial now published in ref. ²⁷. The revised sentence now reads: “Studies evaluating different triplet combinations are underway³⁷”. Original ref. ³⁸ has been removed from the References list (and references numbering updated accordingly). Original reference (now removed) 38. Lee, Y. J. et al. A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01). J. Gynecol. Oncol. 32, e31 (2021).